Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 8;118(2):e29-35.
doi: 10.1161/CIRCULATIONAHA.107.189624. Epub 2008 Jun 19.

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy

Judith S Currier, Jens D Lundgren, Andrew Carr, Daniel Klein, Caroline A Sabin, Paul E Sax, Jeffrey T Schouten, Marek Smieja; Working Group 2

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy

Judith S Currier et al. Circulation. .

Erratum in

  • Circulation. 2008 Aug 5;118(6):e108
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative rate of MI according to protease inhibitor exposure. The shown dose response equates to an adjusted* relative rate (RR) per year of exposure to protease inhibitor (PI) therapy of 1.16 (95% CI 1.10 to 1.23). Reproduced from Friis-Møller et al with permission of the publisher. Copyright © 2007 Massachusetts Medical Society. All rights reserved.
See this image and copyright information in PMC

References

    1. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328. - PubMed
    1. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351:1959. - PubMed
    1. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, Maa JF, Hodder S. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512. - PubMed
    1. Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [published correction appears in N Engl J Med. 2004;350:955] N Engl J Med. 2003;349:1993–2003. - PubMed
    1. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735. - PubMed

Publication types

MeSH terms

Grants and funding